On November 14, 2024, Imexpharm proudly received recognition as one of the "Top 40 Enterprises Excelling in Aligning Business Goals with Social Responsibility" at the Saigon Times CSR 2024 Awards. This acknowledgment highlights Imexpharm’s strong commitments and outstanding achievements in realizing sustainable development goals aligned with its mission of comprehensive healthcare for the Vietnamese people.

The Saigon Times CSR program, organized annually by The Saigon Times - a prestigious economics and foreign affairs magazine under the People’s Committee of Ho Chi Minh City - recognizes and honors 40 domestic and international enterprises for their practical contributions to the economy, society, and environment. This recognition enhances their reputation, competitive edge, and promotes a culture of corporate social responsibility (CSR). In its sixth year with the theme “Invest in a Sustainable Future,” the Saigon Times CSR 2024 not only celebrates humanitarian contributions to the community but also highlights Imexpharm’s impact in advancing Vietnam’s pharmaceutical sector, ensuring a stable domestic medicine supply, and building production capacity for the global supply chain.

With 47 years of growth, Imexpharm remains steadfast in its sustainability strategy, focusing on five core pillars: People, Environment, Prosperity, Partnerships, and Building a Strong and Compassionate Organization. The philosophy of “Sharing for Sustainability” serves as the company’s guiding principle, reflecting a long-term vision to elevate the competitiveness of Vietnam’s pharmaceutical sector while aligning with broader goals, such as contributing to the United Nations Sustainable Development Goals (UN SDGs).

Imexpharm is dedicated to improving public health, striving for a fair and inclusive society that benefits not only its business but also the wider community. These commitments are brought to life through practical actions, including providing high-quality medicines to underprivileged communities, implementing environmental protection initiatives, and sponsoring educational programs over decades.
In particular, as climate change becomes increasingly integrated into legal frameworks for the pharmaceutical industry, Imexpharm prioritized the "greening" of their entire production and supply chain, contributing to both human health and responding to changes in environmental conditions and emerging disease threats
The establishment and operation of EU-GMP-certified factories underline Imexpharm's unwavering commitment to adhering to stringent production quality standards while prioritizing environmental protection. With three EU-GMP factory clusters and 11 EU-GMP-certified production lines, the company minimizes CO2 emissions and employs advanced wastewater treatment systems meeting ISO 14001:2015 environmental management standards.
The fusion of cutting-edge technology with environmental responsibility not only enhances Imexpharm's competitive edge against global pharmaceutical giants but also creates sustainable value for the community and Vietnam's pharmaceutical industry. This aligns with the company’s ambitious strategy to integrate into the global supply chain, aiming to triple revenue by 2030.
Mr. Nguyen An Duy, CFO of Imexpharm, stated: “Investing in people and the environment reflects Imexpharm’s vision and mission to address community challenges while building trust with our customers. These investments contribute to sustainable social development, foster innovation, and improve business performance. Imexpharm is committed to prioritizing CSR, implementing sustainable solutions, and creating long-term value for the community—true to our business philosophy: ‘Even 1,000 years later, the lotus still blooms.’”
Earlier, on August 2, 2024, Imexpharm was also named one of the Top 50 Sustainable Development Enterprises in Vietnam for 2024 by Nhịp Cầu Đầu Tư magazine.